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The pathogenesis of hyperacute renal rejection consists of a 
nonspecific effector cascade that invokes most of the compo-
nents of a typical acute inflammatory response. Platelet-acti-
vating factor (P AF) represents the most recent and perhaps the 
most significant mediator and promoting agent ofthis phenom-
enon. These studies evaluated SRI 63-441, a novel, synthetic, 
and the most potent P AF receptor antagonist available, alone 
and in combination with other prostanoids, for their ability to 
influence this response and to prolong renal xenograft survival 
and function in a model of pig-to-dog heterotransplantation. 
Inhibition of PAF by SRI 63-441 alone, at the dosage and 
schedule used in these experiments, did not significantly pro-
long xenograft survival or function. However, the combination 
of SRI 63-441 with either prostacyclin (PGI2) or prostaglandin 
El (PGE1) infusion demonstrated significant synergism, and 
resulted in a 6-9-fold increase in kidney survival and a 3-20-
fold increase in urine output. Neither PGI2 nor PGE1 infusions 
alone significantly influenced this xenograft model. Electro-
magnetic flow studies demonstrated significantly delayed dim-
inution in renal artery blood flow in the combination-treated 
animals. Serial and end-stage histologic examination of kid-
neys receiving combination therapy demonstrated a delayed 
onset of the pathologic deterioration and an overall ameliora-
tion of the entire process. These studies demonstrate that sig-
nificant abrogation of a rapid and violent form of hyperacute 
rejection can be achieved solely by the pharmacologic manipu-
lation of the inflammatory mediator response. 
T HE PATHOPHYSIOLOGIC EVENTS leading to hy-peracute allograft rejection have been relatively 
well characterized and differ little today from 
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the process originally described almost 20 years ago. I- 3 
The initiating event is clearly a specific immunologic 
reaction consisting of antibody-mediated injury directed 
against antigens on the vascular endothelium of the 
transplanted organ.4- 6 This immunologic phenomenon 
leads to the accumulation of platelet-polymorphonu-
clear leukocyte-erythrocyte plugs in small arteries and 
capillaries, followed by intravascular coagulation and 
ischemic necrosis.1,4,S,7 
The sequence of events leading from the initial spe-
cific immunologic reaction to the final characteristic 
pathologic result of hyperacute rejection of a kidney, 
which can best be described as a failure or breakdown of 
the microvasculature, represents a nonspecific, intense, 
and complex inflammatory response, This effector cas-
cade invokes most, if not all, of the classical mediator 
systems of the acute inflammatory process (i.e., comple-
ment, coagulation, fibrinolytic, and kallikrein-kinin 
systems).8,9 During this process, a large number ofbio-
logically active molecules are generated that are respon-
sible for the increased vascular permeability, arteriolar 
vasoconstriction, damage to the cytoskeleton, fibrin de-
position, generation of oxygen-free radicals, and the re-
cruitment, activation, and release of various inflamma-
tory cells, which all contribute to the entire pathogenesis 
of hyperacute kidney rejection.8,9 
Many of these chemical mediators of inflammation, 
including kinins, various chemotactic factors, anaphyl-
atoxins, serotonin, and arachidonic acid metabolites 
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(prostaglandins, leukotrienes, thromboxanes) have been 
proposed as central candidates in the overall process of 
hyperacute rejection, and have served as the targets in 
attempts to develop therapeutic interventions to regu-
late organ function. The newest and perhaps most im-
portant inflammatory mediator to be nominated as a 
central candidate in the overall evolution of hyperacute 
rejection is acetyl glyceryl ether phosphorylcholine 
(AGEPC).10 Also known as platelet-activating factor 
(PAF), as it will be referred to here, because it was ini-
tially discovered by its ability to cause potent platelet 
aggregation and release, it represents the most recently 
described and novel class of potent lipid autocoids.8,11,12 
The implication that PAF plays a central role in the 
induction of tissue injury is attributed to a spectrum of 
biological activities that may manifest all ofthe cardinal 
signs of acute inflammation.8,1O-12 PAF is produced by a 
variety of inflammatory cells including platelets and 
neutrophils. It is also produced by endothelial cells, 
which supports its importance as a key regulator of the 
microvasculature, and more importantly, its disruption 
under pathophysiologic circumstances. Specific biologi-
cal activities of PAF that are germane to its role in hy-
peracute rejection include: platelet and neutrophil re-
lease and aggregation, release of thromboxane A2 and 
other eicosanoids, increase of vascular permeability, va-
soconstriction, increase in hematocrit, systemic hypo-
tension, and generation of oxygen-free radicals. 
With the availability of specific receptor antagonists 
ofPAF, further insight into the role ofPAF in the patho-
genesis of hyperacute rejection is now possible. The po-
tential for a new method of controlling the effector cas-
cade of hyperacute rejection by pharmacologic inter-
vention can now be exploited also. Pig-to-dog renal 
heterotransplantation results in a rapid and violent form 
of cortical necrosis and ischemic destruction of the 
organ, which mimics the situation in humans and is due 
to preformed humoral antibodies in the recipient.4,5,13 It 
represents an appropriate severe model in which to eval-
uate new methods of therapeutic intervention. The stud-
ies reported evaluated the effect of a novel and potent 
synthetic PAF receptor antagonist, alone and in combi-
nation with other prostanoids, on this renal xenograft 
model. 
Materials and Methods 
Animals 
Female, white outbred SPF pigs that weighed 15-20 
kg were purchased from Shadyside Farms, Ohio and 
Served as donors. Male beagles that were bred for re-
search and weighed 13-16 kg were pu rchased from Lab-
oratory Research Enterprise, Kalamazoo, Michigan and 
served as recipients. All animals were housed in a central 
animal facility and were allowed to acclimatize for at 
least 1 week before experimentation. They received 
standard animal chow and water ad libitum and were 
fasted for 24 hours before surgery. 
Surgical Procedures 
All animals for both the donor and recipient proce-
dures were anesthetized with intravenous sodium pen-
tobarbital (30 mg/kg). Recipient dogs were maintained 
with 30% oxygen through an endotracheal tube. During 
the experimental procedure, dogs were monitored for 
depth of anesthesia by EKG and arterial pressure. Addi-
tional anesthetic (pentobarbital, 3 mg/kg IV) was given 
as required. 
Donor pigs received intravenous Ringer's lactate 
(1000 mL), mannitol (12.5 g), and Thorazine® (50 mg). 
After systemic heparinization (5000 units) and in situ 
cooling with cold (4 C) Ringer's lactate through an aor-
tic cannula, the kidneys were removed en bloc. The kid-
neys were then separated and transplanted simulta-
neously into two recipient dogs, always with less than 1 
hour of cold ischemia time. A paired design was there-
fore performed for each experiment, by assigning one 
kidney as the control and the other as the test (treated) 
kidney. 
All pig-to-dog kidney heterotransplantations were 
performed by a standard technique. The porcine renal 
artery was anastomosed end to end to the recipient right 
common iliac artery, and the renal vein was anasto-
mosed end to side to the right common iliac vein. The 
anastomosis time was always less than 30 minutes. The 
dogs were kept anesthetized and the kidney was left ex-
ternal to the dog for observation. The ureter was cannu-
lated with polyethylene tubing and urine was collected 
throughout the transplant period. For intra-arterial ad-
ministration of prostaglandins, an 18-gauge polyethyl-
ene catheter was inserted through the middle sacral ar-
tery and threaded towards the orifice of the right com-
mon iliac artery. To ensure that solution infused into the 
terminal aorta would exclusively run into the graft renal 
artery, the left common iliac, middle sacral, and other 
smaller arteries originating at or near the aortic bifurca-
tion were ligated near their origin. For those experi-
ments where renal vein and artery platelet counts were 
measured, 18-gauge polyethylene catheters were intro-
duced into the right femoral vein and its tip positioned 
at the venous anastomosis, and into the left common 
iliac artery and its tip positioned at the orifice of the 
right common iliac artery. 
Each dog underwent native nephrectomy after the 
porcine kidney had been revascularized. A change in 
color or motling of the transplanted pig kidney was con-
sidered evidence of the onset of rejection. However, the 
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end point of the experiment was signaled by a cessation 
of urine flow or by the onset of frank hematuria. 
Drug Administration 
Prostaglandins. Naturally occurring prostacyclin 
(PGI2) and prostaglandin E, (PGE1) or Prostin-VR were 
supplied by the Upjohn Company, Kalamazoo, Michi-
gan (M. J. Ruwart). PGh was reconstituted and infused 
in a O.lM glycine buffer, adjusted to a pH of 10.5 with 
2M Tris solution to enhance its stability. PGE1 was re-
constituted in a stock solution of 1 mg in 100 ILL of 
ethanol. This solution was then diluted to the appro-
priate concentration in 0.9% sodium chloride for infu-
sion. 
All prostaglandins, freshly reconstituted for each ex-
periment, were administered by constant infusion 
through the catheters placed into the aorta, and the dos-
age was titrated according to blood pressure tolerance. 
Control animals for the prostaglandin experiments re-
ceived infusions of the particular prostaglandin vehicles. 
PAF antagonist. SRI 63-441 was provided by the 
Sandoz Research Institute, Sandoz, Inc. (East Hanover, 
NJ). This synthetic compound represents the most po-
tent receptor antagonist of PAF responses known to 
date. SRI 63-441 (molecular weight 662) is a substituted 
[tetrahydrofuranyl-(methoxyphosphinyloxy)ethyl] 
quinolinium compoundl4 and is structurally similar to 
P AF. Structural analyses and purity (greater than 98%) 
were determined by NMR spectroscopy and thin-layer 
chromatography.14 SRI 63-441 is readily soluble in 
water or sodium acetate buffer at concentrations as high 
as 5% and can only be given parenterally. In four species 
tested (rats, guinea pigs, dogs, and primates), SRI 63-441 
exhibited dose-dependent inhibition of all major physio-
logic responses to PAF (i.e., hypotension, hemoconcen-
tration, bronchoconstriction, and increased vascular 
permeability). '4 For all studies reported here SRI 63-441 
was reconstituted as a 10 mg/mL solution in 0.68% so-
dium acetate and 0.9% sodium chloride (pH 5.3). Before 
its administration, this solution was placed in a warm 
water bath (24-25 C) for 5 minutes and then adminis-
tered as a bolus intravenous injection. Control dogs re-
ceived the sodium acetate buffer intravenously. 
Experimental Design 
Four experimental groups are reported: Group I: the 
administration of SRI 63-441 alone was compared with 
controls; Group II: the combination of SRI 63-441 and 
PGI2 was compared with controls; Group III: the combi-
nation of SRI 63-441 and PGE, was compared with 
controls; Group IV: the combination of SRI 63-441 and 
PGE, was compared with PGE1 alone. 
Both prostaglandins (PGI2 , PGE1) were administered 
at a dose of 0.5-1.0 Ilg/kg/min (depending on systemic 
blood pressure) by continuous intra-arterial infusion 
commencing at 30 minutes before revascularization. 
SRI 63-441 was administered at 5 mg/kg/dose by intra-
venous bolus beginning at 5 minutes before and then 5 
minutes after, and then every 15 minutes after revascu-
larization. For each study, experiments were performed 
on control and test animals simultaneously. 
Kidney survival was assessed for each experiment as 
described above. Urine was collected for the entire 
transplant period, and the total volume was used as an 
indicator of renal function. For six experiments in 
Group II and for three experiments in Group IV, plate-
let counts in the renal artery, renal vein, and peripher-
ally were determined serially (every 10 minutes for the 
first hour and then every 30 minutes for up to 4 hours in 
the treated groups). Renal arterial blood flow in the 
transplanted kidneys was monitored electromagneti-
cally using a Cliniflow II, Model FM701D Electromag-
netic Flowmeter (Carolina Medical Electronics Inc., 
NC). Flows (in milliliters per minute) were determined 
every 10-15 minutes in six separate experiments in 
Group IV (controls received PGE, infusion). Serial kid-
ney biopsies (every 15 minutes) were performed in an 
extra group of animals that are not included in survival 
statistics. Biopsies were also done at the end point of the 
experiment, (using the criteria outlined above) in all 
groups studied. 
Pathologic Studies 
Tissue preparation. Histologic evaluation of serial 
biopsies from one experiment and of sections of kidneys 
taken at the end stage of additional experiments are 
presented. In the serial studies, wedge biopsies were ob-
tained at baseline (back table), and at 5, 15, 30, 45, 60, 
75, and 90 minutes after revascularization. Tissues were 
formalin-fixed, paraffin-embedded, cut at 3 JLm, and 
stained with hematoxylin and eosin. 
Histologic parameters. One microscopic section from 
each biopsy was selected. The slides were randomized 
and evaluated in blind fashion. The percentage of glo-
meruli with segmental or global thrombosis was deter-
mined. The glomeruli with necrosis or PMNs were also 
counted. Acute tubular necrosis (A TN), characterized 
by disintegration and sloughing of epithelial cells, was 
graded as mild (rare foci), moderate (numerous foci), or 
severe (confluent). Blood in the tubular lumens and mi-
toses were noted. The interstitium was rated as normal, 
congested, or hemorrhagic; the latter was graded as mild 
(few foci), moderate (numerous foci), or severe (con-
fluent). Arteries and arterioles containing thrombi were 
noted. 
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FIG. I. Survival of renal xe-
no grafts after pig-to-dog 
kidney transplantation as-
sessing the effect of single 
and combination treatment 
with a PAF receptor antago-
nist (SRI 63-441) and two 
prostanoids (PGI 2 and 
PGEd. Results are ex-
pressed as total survival 
time (mean minutes ± SE). 
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All statistical evaluations were performed on an IBM 
PC-A T microcomputer using statistical analysis soft-
ware (SPSSjPC+, SPSS Inc., Chicago, IL and BMDPj 
PC, BMDP Statistical Software, Los Angeles, CA). The 
mean and standard errors for urine volume and kidney 
survival for control and treated groups were compared 
using a nonparametric statistical test (McNemar) for the 
comparison of mean differences between two groups. 
The mean and standard errors for platelet counts were 
compared using a repeated measure design analysis. For 
all tests, a p value of less than 0.05 was considered sta-
tistically significant. 
Results 
Renal Xenograft Survival 
Figure 1 depicts the survival for transplanted porcine 
kidneys in the four groups studied. The control dogs in 
all experiments consistently demonstrated violent rejec-
tion of the pig kidney within a mean time of approxi-
mately 30 minutes. The administration of SRI 63-441 as 
a single agent at the dosage and schedule described here 
did not result in a significant increase in graft survival. 
The addition of either prostanoid (PGI2 or PGE[) to SRI 
63-441 treatment resulted in a marked synergism and a 
significant increase in kidney survival. SRI 63-441 and 
PGI2 resulted in a greater than sixfold (217.1 ± 39.4 vs. 
37.4 ± ILl minutes, p < 0.001) and SRI 63-441 and 
PGE[ in a greater than sevenfold (268.6 ± 27.7 vs. 37.2 
± 5.6 minutes, p < 0.001) increase in renal xenograft 
survival when compared with their respective controls. 
PGI2 or PGE1 infused as single agents had no significant 
*p<0.001 
SRI 
63-441 
SRI 
63-441 + 
PGb 
n= 19 
SRI 
63-441 + 
PGE 1 
effect on kidney survival. In fact, in Group IV, the com-
bination of SRI 63-441 and PGE[ resulted in a greater 
than ninefold increase in kidney survival when com-
pared with PGE[ infusion alone (280.4 ± 3l.8 vs. 3l.0 
± ILl minutes, p < 0.001). PGE[ in this experiment 
behaved no differently than the control vehicles in the 
other experiments. 
Renal Xenograft Function 
Renal function as determined by total urine output 
for each transplant is depicted in Figure 2. The results 
parallel those observed for kidney survival already pre-
sented above. SRI 63-441 alone did not significantly 
improve renal function. The combination of SRI 63-441 
and PGI2 resulted in a greater than threefold (99.5 
± 30.4 vs. 29.5 ± 13.7 mL, p < 0.05) and of SRI 63-441 
and PGE[ in a greater than 20-fold (436.2 ± 134.8 vs. 
2l.2 ± 7.3 mL, p < 0.02) increase in total urine output. 
Neither prostanoid alone resulted in a significant in-
crease in urine output. The combination of SRI 63-441 
and PGE[ resulted in a 12-fold increase in total urine 
output (370.9 ± 78.9 vs. 32.7 ± 6.4 mL, p < 0.003) when 
compared with PGE[ alone, which did not differ signifi-
cantly from vehicle controls. 
Platelet and Flow Studies 
The serial platelet counts for six experiments in 
Group II (SRI 63-441 + PGI2 vs. controls) and three 
experiments in Group IV (SRI 63-441 + PGE 1 vs. 
PGE[) are depicted in Figures 3 and 4, respectively. 
There was a significant difference between the renal ar-
tery and renal vein platelet counts in Group II for both 
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control and treated animals, with a more pronounced 
gradient evident in the control group. No significant 
gradient in platelet count between renal artery and vein 
was observed in Group IV dogs. 
The flow studies from six experiments in Group IV 
(SRI 63-441 + PGE, vs. PGE,) are depicted in Figure 5. 
With the drug combination treatment group, as already 
evident in renal xenograft survival and function, blood 
flow to the xenografted kidneys was consistently main-
tained at significantly higher levels than in the control 
group (in this case already receiving a vasoactive agent, 
PGE1). This is depicted up to 100 minutes after revascu-
larization in Figure 5, since before that time, the PGE[ 
alone group had already demonstrated severe diminu-
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FIG. 2. Function of renal xe-
nografts after pig-to-dog 
kidney transplantation from 
experiments described in 
Figure I. Results are ex-
pressed as total urine output 
for the entire transplant pe-
riod (mean milliliters ± SE). 
tion of graft flow. However, the combination treatment 
group maintained a degree of significant flow for most of 
the duration of the experiment. 
Pathologic Evaluation 
Microscopically, in the serial experiment, baseline 
biopsies from both control and treated animals con-
tained normal glomeruli, with normal cellularity, and 
patent, empty capillary loops (Fig. 6). After reperfusion, 
both kidneys exhibited progressive obliteration of capil-
lary loops by eosinophilic granular material mixed with 
red blood cells (Fig. 7). Similar thrombi were found in 
arteries and arterioles as early as 15 minutes. Tubules 
SRI 63-441 + PGI, 
• P 
FIG. 3. Platelet counts 
(mean ± SE) determined for 
the renal artery (RA), renal 
vein (RV), and peripherally 
(P) for six sets of expcri-
ments in Group II (SRI 
63-441 + PGb vs. control). 
0 10 20 30 40 50 60 90 120 a 10 20 30 40 50 60 90 120 150 ISO 200 210 240 
Vol. 206 • No.4 PROLONGATION OF RENAL XENOGRAFT SURVIVAL 487 
400 
'b 350 
,.... 
+1 
UJ 
FIG. 4. Platelet counts (j) 300 
(mean ± SE) determined for m 
the renal artery (RA), renal 6 
vein (RV), and peripherally ...J 
(P) for three sets of experi- i 
ments in Group IV (SRI E 
63-441 + POE, vs. PGE,). ~ 
CD 
* 
250 
200 I 
a: 150 
100 
PGE, 
300 
250 
200 
150 
100 
n = 3 
50 
SRI 63-441 + PGE, 
• p 
==0= RA 
~RV 
o 10 20 30 40 50 60 90 120 180 o 10 20 30 40 50 60 90 120150180 210 240 
remained well preserved until 1 hour. There was pro-
gressive edema, then congestion, then hemorrhage in 
the interstitium. At the end stage, when renal function 
ceased, all specimens showed diffuse thrombosis of glo-
meruli, arteries, and vasa rectae. There were interstitial 
hemorrhages and early changes of A TN. 
Sequential biopsies. Biopsy specimens at 5, 45, and 90 
minutes are shown in Figures 8-10. Qualitatively, the 
glomerular changes were similar in the control and 
treated groups. However, the development of glomeru-
Flow (ml/min; Mean + SE) 
50 
40 
30 
FIG. 5. Electromagnetic 
flow studies (mean mL/min 
± SE) for six sets of experi-
ments in Group IV (SRI 
63-441 + PGE, vs. PGE,). 20 
10 
a 
p<0.02 
p<0.01 
20 
lar thrombosis proceeded at a slower rate in the treated 
kidneys. Table 1 shows the results from one epxeriment. 
The control animal reached end stage with thrombosis 
in 94% of the glomeruli at 45 minutes, whereas the pro-
cess reached completion in the treated kidney at 90 
minutes. At end stage, red blood cell thrombi were more 
prominent in the treated kidney (Fig. 10). 
Necrosis of tubular epithelial cells was noted in the 
control kidney with blood in the lumens at 60 minutes. 
These changes persisted until the end of the experiment. 
SRI 63-441 + PGE 1 
p<0.01 
40 60 80 100 
Time After Revascularization (Minutes) 
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It is important to note that significant necrosis was not 
noted in the treated kidney. 
There was a difference between the two kidneys in the 
amount and onset of interstitial hemorrhage. Focal 
hemorrhages were noted in the control kidney at 15 
FIG. 6. Baseline biopsy 
specimen showir..g nor-
mal, empty glomerulus 
(hematoxylin and eosin. 
original magnification 
X960). 
minutes; this progressed to diffuse hemorrhage by 45 
minutes and persisted (Fig. 9). In contrast, the treated 
kidney showed only focal hemorrhages at 30 minutes, 
and again at 90 minutes. There were no significant dif-
ferences between the control and treated kidneys with 
FIG. 7. Glomerulus filled 
with thrombi composed of 
RBCs in a pale granular 
matrix (hematoxylin and 
eosin, original magnifica-
tion X960). 
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FIGS. 8A and B. Serial 
study, biopsy specimens at 
5 minutes: A. control; B. 
treated. Note thrombi in 
some glomerular capillar-
ies (arrows), and relatively 
normal tubules and inter-
stitium (hematoxylin and 
eosin, original magnifica-
tion X62S). 
regard to the presence of thrombi in arteries and arteri-
oles. 
End-stage biopsies. The end-stage biopsies obtained 
after implantation represented a later stage than the se-
quential biopsies. In these sections, RBCs were a promi-
nent component of the glomerular thrombi in the 
treated kidneys, whereas in the control groups the 
thrombi were composed of mostly granular eosinophilic 
material consistent with platelet-fibrin thrombi, similar 
to the changes noted in the sequential biopsies. There 
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was more interstitial hemorrhage in the treated dogs 
than in the controls in five cases, and less hemorrhage in 
four cases. Three of the treated kidneys and none of the 
control kidneys exhibited up to 20% glomeruli free of 
thrombi. 
Discussion 
FIGS. 9A and B. Serial 
study, biopsy specimens at 
45 minutes: A. control; B. 
treated. Note hemor-
rhages in the interstitium 
in the control kidney. 
Both glomeruli contain 
thrombi (hematoxylin 
and eosin, original magni-
fication X625). 
The candidacy of platelet-activating factor (PAF) as a 
pivotal biologic mediator in the pathogenesis of anti-
body-mediated hyperacute allograft rejection has been 
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FIGs. lOA and B. Serial 
study, biopsy specimens at 
90 minutes: A. control; B. 
treated. Note interstitial 
hemorrhages and blood in 
the tubules in the control 
kidney (hematoxylin and 
eosin, original magnifica-
tion X625). 
clearly established. In vitro studies have demonstrated 
that PAF is released when endothelial cells are incu-
bated with antibody to cell surface angiotensin convert-
ing enzyme. 15 This has important implications for hy-
peracute rejection, in which the specific initiating event 
is a transplantation antigen-antibody interaction on the 
endothelial surface. In a model of hyperacute renal allo-
graft rejection in sensitized rabbits, PAF was identified 
in the blood effluent from the transplanted kidney, fol-
lowing antibody and complement fixation to the endo-
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TABLE 1. Progression of Histologic Findings in Sequential Biopsies of Control and Treated Kidneys 
Control Treated 
Glomerular Glomerular 
Time Thrombosis Interstitial Thrombosis Interstitial 
(Min) (%) ATN Hemorrhage (%) ATN Hemorrhage 
5 26 0 0 
15 69 0 Focal 
30 83 0 Focal 
45 94 0 Severe 
60 91 Focal Severe 
75 88 Focal Moderate 
90 78 Focal Severe 
thelium of glomerular and peritubular capillaries.1O No 
PAF could be detected in rabbits without clinical or 
histologic signs of rejection. The PAF release was fol-
lowed by the recruitment of platelets, endothelial stick-
ing, and obliteration of capillaries by platelet-PMN 
plugs and evidence of cellular degranulation. 10 
The importance of PAF, even in the absence of in-
flammatory cells, was demonstrated in a model of ex 
vivo perfusion of the rabbit heart with transplantation 
alloantibodies. 16 The release of PAF followed bradycar-
dia, conduction arrhythmias, decreased coronary flow, 
and cessation of heart action. These alterations in car-
diac function and, moreover, the release of PAF, were 
prevented by complement inactivation. PAF itself in-
duced a negative inotropic effect and reduction of coro-
nary flow in isolated guinea pig heart muscle by a direct 
action on the Ca++ slow channel. Moreover, the injec-
tion of synthetic, purified PAF into the renal artery of 
rabbits reproduced a pathologic picture identical to that 
seen in a Shwartzman reaction of the kidney.17 The 
pathophysiology of hyperacute renal rejection in 
humans was originally described as a Shwartzman reac-
tion. 1 
The nonspecific effector inflammatory cascade that 
ensues once an antigen-antibody reaction has initiated 
hyperacute rejection has served as the target for thera-
peutic intervention by many different approaches. Clas-
sically, the platelet-coagulation system has been consid-
ered to be the most important and has received the 
greatest attention. These therapeutic modalities have in-
cluded heparin, aspirin, dextran, citrate, defibrinating 
agents, cobra venom factor, induction of thrombocyto-
penia by antibodies etc., and various prostaglandins. 18-21 
All these approaches have been either too toxic or 
the results too inconclusive to be accepted for general-
ized use. 
The difficulty in overcoming the inflammatory pro-
cess in hyperacute rejection and in explaining the dis-
crepancies in therapeutic results rest not only in the 
complexity of the biologic reactions, but also in their 
13 0 0 
46 0 0 
60 0 Focal 
73 0 0 
80 0 0 
77 0 0 
97 Focal Moderate 
resiliency and redundancy. That is, there are numerous 
alternative mediator pathways that can backup the same 
set of functions. Thus, the inhibition of one arm of an 
inflammatory reaction can easily be replaced by the re-
lease of other inflammatory autocoids with complete 
mediation of a disease process. P AF may represent 
somewhat of an exception to this hypothesis, because of 
its potency and its unique potential for mediating al-
most every aspect of acute inflammatory reactions. 
Nonetheless, the argument for polypharmaceutical ther-
apy of hyperacute rejection is clear. 
The current study represents the first known report 
describing the therapeutic efficacy of a receptor antago-
nist ofPAF in any in vivo model of hyperacute rejection. 
These studies not only lend further support to the prom-
inent role ofPAF in the regulation of the inflammatory 
response leading to hyperacute rejection, but also intro-
duce a new and potentially significant therapeutic ap-
proach to this entity. The agent used in these studies, 
SRI 63-441, is currently the most potent and specific 
PAF receptor antagonist available. It represents a family 
of compounds that can be synthesized and modified to 
meet desired specifications, i.e., an oral compound re-
cently has been produced. 
At the single dosage and schedule of SRI 63-441 eval-
uated in these studies, inhibition of PAF alone was not 
sufficient to improve renal xenograft survival or func-
tion, although a trend did exist. From studies in rats and 
other recent studies in dogs, we have determined that 
the critical consideration for the efficacy of SRI 63-441 
is to administer it at a much higher dose and before 
revascularization (unpublished data). However, the ad-
dition of either one of two prostanoids, PGh or PGE1 , 
resulted in a synergistic response and a manyfold in-
crease in renal xenograft survival and function. Al-
though a higher dosage and more appropriate schedul-
ing of SRI 63-441 may improve the effectiveness of sin-
gle drug therapy, the need for multiple drug treatment 
eluded to above may be necessary to adequately modu-
late this violent inflammatory process. 
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There are many reasons for choosing PGI2 and PGE1 
as complimentary agents to SRI 63-441. They both in-
hibit platelet function by stimulation of receptor-cou-
pled adenylate cyclase and increase intracellular cAMP, 
a receptor mechanism different from that required for 
SRI 63-441 inhibition.22 To varying degrees, they both 
exhibit other properties that establish them as excellent 
therapeutic candidates for such inflammatory processes. 
These biological activities include vasodilatation, fibri-
nolytic action, inhibition of the generation of certain 
deleterious metabolites of the arachidonic acid cascade, 
inhibition of oxygen-free radical generation, and the 
property known as cytoprotection.22 Moreover, both 
these prostaglandins have been evaluated in other 
models of hyperacute rejection. Treatment with PGE1 
prolonged hamster-to-rat cardiac xenograft surviva1.23 
PGI2 administration significantly prolonged kidney sur-
vival in both a model of hyperacute renal allograft rejec-
tion in presensitized dogs and in cat-to-dog xeno-
grafts,21,23 but had no effect on guinea pig-to-rat cardiac 
xenograft surviva1. 23 Neither PGI2 nor PGE1, when ad-
ministered alone as a constant infusion without combi-
nation SRI 63-441 treatment, had a significant effect on 
pig-to-dog renal xenograft survival or function as de-
scribed in our studies. Furthermore, the therapeutic ef-
fectiveness of these prostaglandins in combination with 
SRI 63-441 was evident only when they were infused 
intra-arterially; peripheral administration of prostaglan-
dins did not exhibit synergism with SRI 63-441 (unpub-
lished results). This is most likely due to inactivation of 
prostaglandins as they pass through the lungs,22 
The pig-to-dog renal xenograft model evaluated in 
these studies probably represents the most severe animal 
model of hyperacute rejection known. Rapid and vio-
lent kidney rejection is the rule and there have been only 
a few reports of successful abrogation of this process. 
Shons and Najarian reported a significant increase in pig 
renal xenograft survival from a mean of 5 minutes in 
controls up to a mean of 45 minutes in dogs treated with 
a variety of antiplatelet agents,19 Merkel et al. reported 
renal xenograft survival times of 120, 90, and 180 min-
utes in three dogs that had preoperative plasmapher-
esis.24 Kux et al. reported a mean rejection time of 85 
minutes in 15 kidneys treated with intra-arterial citrate 
infusion; these experiments were limited by significant 
toxicity.20 The control xenografts for the latter two sets 
of experiments rejected in less than 10 minutes.2o,24 
Consistent and reproducible results were achieved in 
the same model in the current studies by combining SRI 
63-441 with either PGI2 or PGE1. Pig kidneys surviving 
for 3-4 hours were consistently achieved with mainte-
nance of good urine output in all combination treat-
ment groups. There were three kidneys in this series of 
experiments that functioned satisfactorily for 6-9 hours. 
These results compare most favorably with any previous 
reports of this particular model. 
Although the differences in the pathologic evaluation 
of treated and control animals were subtle, there is no 
doubt that on serial histologic examination, treated ani-
mals demonstrated a delay in the evolution of the final 
morphologic deterioration. Futhermore, the end-stage 
histologic examination in treated kidneys demonstrated 
an overall amelioration, albeit minor, of the entire 
pathologic process. The histologic findings correlated 
with the clinical course. The significant improvements 
in renal xenograft survival and function were also paral-
leled by a significantly delayed diminution in renal ar-
tery blood flow and a significantly improved gradient of 
the platelet count between renal artery and vein in com-
bination treated animals. 
Emphasis on platelet counts and gradients may not be 
as important as once believed. It is clear that although 
PAF is a potent modulator of platelet aggregation and 
release, it can promote the pathophysiologic process of 
hyperacute rejection by various other pathways.8-12 Fur-
thermore, rats with a defect in platelet aggregation ex-
hibited the same time course and morphologic features 
of hyperacute cardiac rejection as in normal rats,6 and 
platelet aggregation was demonstrated not to be essen-
tial in a model of renal xenograft rejection.25 
In summary, these studies further confirm the central 
role of platelet-activating factor in the inflammatory 
cascade that destroys kidneys undergoing hyperacute 
rejection. Furthermore, this report introduces a novel, 
reproducible, and potentially effective therapeutic ap-
proach to this difficult problem, which relies on a better 
understanding of the basic pathophysiologic process of 
inflammation and which utilizes as its basis, a synthetic 
receptor antagonist that specifically inhibits the potent 
and unusually diverse spectrum of biologic activities of 
one of the key mediators of classical inflammation. 
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endothelium. Would you comment on why the graft fails even though 
there is some prolongation of survival? 
DR. COURTNEY M. TOWSEND, JR. (Galveston, Texas): That was a 
very nice study. There was a lot of work in it. It was very well presented. 
I wondered why you had to give the prostaglandins in addition to the 
PAF antagonist in the pig-to-dog model and did not apparently do that 
in the rat model. 
DR. WILLIAM E. NEVILLE (Newark, New Jersey): This was a beauti-
fully presented paper and their results were stirn ulating. 
As I look back at what our group did in the 1960s and early 1970s on 
heterologous cardiac transplants in animals, I realize now that I should 
have continued with this work. However, we did not have the drugs 
that today seem to prevent early rejection between certain heterolo-
gous animals. We initially inserted the hearts of calves, sheep, goats, 
and pigs orthotopically into dogs on cardiopulmonary bypass using 
only Ringer's lactate to prime the pump oxygenator. The hearts were 
initially pink and contracting but deteriorated rapidly. Histologic and 
electro microscopic studies showed microcirculatory red cell agglutina-
tion without fibrin despite platelet aggregation and inflammatory reac-
tion. We then reversed the experiements and placed dog hearts into 
calves, sheep, goats, and dogs using the same technique. All of the 
transplanted hearts were easily defibrillated and adequately main-
tained the circulation until the dogs were killed hours later. Micro-
scopic examination of the dog hearts showed few ultrastructural 
changes. The capillaries were invariably patent with no significant 
alterations of the endothelial cells. The myocardium only showed 
some patchy interstitial edema and slight mitochondrial swelling and 
glycogen depletion. The reason for this striking contrast in the two 
groups was not clear; but we reasoned and published that it might have 
something to do with the disproportion between the red blood cells and 
capillaries, thus disregarding an antigen-antibody reaction. 
I would like to see the group from Pittsburgh use this relatively new 
drug alone or in combination with other antlplatelet drugs to see 
---- ------~~~-------
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whether the Schwartzman reaction could be prevented in xenograft 
hearts inserted into dogs on cardiopulmonary bypass. We definitely 
need heterologous organs for transplantation but we do have much to 
learn regarding the use of these organs in humans. 
DR. NICHOLAS L. TILNEY (Boston, Massachusetts): I also enjoyed 
the paper very much. We have been looking at a slightly different 
model in a rat heart graft system, so-called accelerated rejection that 
occurs about 36 hours after transplantation instead of in a few minutes 
as occurs in a presensitized rat. 
In the beginning of the process, we found more or less what these 
authors have found, a very accelerated rejection that is primarily a 
humoral event. There are a few infiltrating cells; however, most of 
which are activated cells bearing interleukin II receptors on their sur-
faces. 
We can abrogate this early rejection and get grafts out to about 3 or 4 
weeks using either cyclosporine in various doses or monoclonal anti-
bodies directed against the interleukin 2 receptors. Regardless of treat-
ment, the grafts ultimately reject at about 3 weeks, but the primarily 
humoral rejection has been converted to a primarily cellular one, an 
extremely interesting observation. 
I would like to aske the authors whether they had a chance to look at 
the infiltrating cell populations during the time their grafts are still 
viable, because I believe they will find these are a very interesting cell 
subgroup and mostly interleukin 2 receptor positive. 
DR. LEONARD MAKOWA (Closing discussion): I would like to thank 
all the speakers for their helpful comments and interesting questions. 
Many of your questions have concentrated on the importance of 
platelets in the overall process of hyperacute rejection and, therefore, T 
will try to cover these together. There is no doubt that platelets playa 
role in this process. However, over the last 20 years, since this entity 
was described, there has been a hangup on the importance of platelets 
and the major role that they play in the overall pathophysiology of this 
process. Many investigators had demonstrated platelet consumption 
by kidneys that were undergoing hyperacute rejection by studying 
platelet gradients between the renal artery and vein of these kidneys. 
Histologically, platelet accumulation and aggregation was a major fea-
ture of the final pathologic process. Nonetheless, it is now clear that the 
role and the importance of platelets in this process is just one small 
component of a much bigger picture, and that the entire evolution of 
hyperacute rejection must be redefined. 
There is considerable evidence in the literature that indicates plate-
lets are not the sole or major contributor to the process of hyperacute 
rejection. These experiments have demonstrated that the identical 
clinical and histopathologic entity of hyperacute rejection can occur in 
the face of platelet depletion, or in animals with a hereditary deficiency 
of platelet function. In fact, it now appears that other cellular compo-
nents, especially the neutrophil, may play an equal or even more 
important role. 
Currently, hyperacute rejection must be considered the end product 
of a set of complex nonspecific inflammatory reactions, which are 
initiated by a specific antigen-antibody reaction. I tried to demonstrate 
some of these contributory inflammatory arms in the first slide, and to 
emphasize their resiliency and redundancy. Thus, many alternative 
backup inflammatory systems can result in the same set of functions 
and final pathologic process. The relative importance of each of these 
inflammatory pathways is as yet unknown, and furthermore, the rela-
tive importance of blocking or inhibiting the biologic activity of any 
one specific mediator remains to be fully defined. 
I must re-emphasize that the designation of the mediator that we are 
discussing today, as platelet activating factor, is a misnomer. PAF plays 
a role in most of the classical mediator systems of the acute inflamma-
tory process, in the generation of arachidonic acid metabolites, and in 
the generation of oxygen free radicals, etc. Although PAF is one of the 
most potent inducers of platelet aggregation and release, and thus by 
this mechanism plays a contributory role in hyperacute rejection, there 
is now clear evidence that establishes PAF as a central candidate in the 
overall evolution of this inflammatory process and as a key biological 
mediator in the pathogenesis of antibody-mediated hyperacute allo-
graft rejection. This lead to our hypothesis that antagonism of PAF-
induced reactions offered a potential therapeutic approach to this en-
tity by inhibiting many of the key inflammatory pathways. 
It is true that one of the actions of the PAF antagonist is to inhibit the 
cyclo-oxygenase pathway, thereby inhibiting the formation of various 
biologically active autocoids of the arachidonic acid cascade, as well as 
interfering with platelet function. Aspirin exhibits these same specific 
properties, but does not influence the numerous other inflammatory 
pathways as the PAF antagonist can. Dr. Najarian's group described a 
set of elegant experiments in Transplantation Proceedings in 1974, 
where the effect of aspirin was evaluated in this same model of pig-to-
dog renal xenografts. They found that the mean graft survival time of 5 
minutes in control animals was increased to 21 minutes by aspirin 
treatment. In fact, the addition of dextran to aspirin treatment further 
increased the mean graft survival time to 45 minutes. At that time, 
these were considered significant results. Obviously, the numerous 
backup pathways could overcome this single-pronged approach in 
such a severe xenograft model. That is why we have initially taken the 
approach of multi pharmaceutical therapy, and demonstrated a syner-
gistic effect by combining a prostaglandin with the PAF antagonist. 
In our studies, we consistently achieved renal xenograft survival of3 
to 4 hours and in a few cases achieved 9-hour survival. These results 
significantly surpassed previously published reports using this same 
pig-to-dog model, which we believe is probably the most severe experi-
mental model of hyperacute rejection known. 
I agree that the dose of prostacyclin that we have reported in these 
particular studies today was too high. We did observe some hypoten-
sion in these animals. Subsequently, we have repeated these studies 
using a much lower dose of prostacyclin and have achieved the same 
efficacy. Similarly, for prostaglandin E[, we have used dosages as low 
as 0.01 ILgjkgjmin, which is well tolerated in humans. 
One of the problems with the studies that I have described to you 
today, is that based on our subsequent rat studies, we probably were 
not using enough of the PAF antagonist. In these studies, we used 5 
mg/kg. From subsequent studies of hyperacute rejection using a model 
of heterotopic cardiac transplantation in hypersensitized rats, we have 
learned two critical points. A much higher dose of the drug can and 
should be given, and the dose given before revascularization is the key 
for efficacy. In fact, we have demonstrated significant prolongation of 
cardiac allograft survival in this model using 15 or 20 mg/kg given 4 
minutes before revascularization. 
It appears that it is much easier to overcome this process in the rat 
heart model using the PAF antagonist alone. As I already mentioned, 
this may be due to a dosage and scheduling inefficiency in the xeno-
graft model reported today. However, in the xenograft model we are 
probably dealing with a much more potent initiating immunologic 
reaction. Therefore, the trigger for this overall process may be different, 
and may require a modified therapeutic approach, i.e., that of utilizing 
polypharmaceutical therapy. Alternatively, we must appreciate the 
contributions of the different microvasculatures of the kidney and the 
heart. 
I agree completely with Dr. Tilney, that the importance of the rat 
model should be emphasized. Unfortunately, these initial studies were 
presented in the closing two slides, but it is apparent that in the rat 
model, we have converted the process of hyperacute rejection into one 
of classical cell-mediated rejection. We have not as yet had the oppor-
tunity to characterize the infiltrating cells in the hearts that underwent 
classical rejection. We are currently in the process of combining the 
PAF antagonist with standard immunosuppression in this model. We 
certainly agree that the combination of the ability to overcome the 
inflammatory process resulting from the initial antibody insult and of 
controlling cell-mediated rejection with appropriate immunosuppres-
sion, at least in the homograft rat heart model, may allow us to over-
come the entire process of hyperacute rejection. 
